Physician profile
Bahman Shamloo
NPI 1871760918
$11,594.01
in general payments reported to CMS, 2019-2025
59 companies · $1,197 in 2025
The $1,197 reported for 2025 was more than what 95% of Anesthesiology providers received nationally (typical 2025 total: $58.09).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,083 · 2020: $1,612 · 2021: $1,616 · 2022: $1,508 · 2023: $2,353 · 2024: $1,224 · 2025: $1,197.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,741 · Education: $33.93.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,740.64 |
| Education | $33.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $1,865.79 | 2019-2025 | General - Pain Management, Wavewriter Alpha Prime 16, Superion Indirect Decompression System |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,386.54 | 2020-2023 | Trulance, Xifaxan |
| Abbott Laboratories | $946.94 | 2019-2024 | Proclaim, Eterna |
| Stimwave Technologies Incorporated | $588.61 | 2019 | |
| Janssen Biotech, INC. | $575.82 | 2022-2025 | Stelara, Tremfya |
| Takeda Pharmaceuticals U.S.A., INC. | $552.92 | 2019-2025 | Entyvio, Gattex, Eohilia |
| Medtronic, INC. | $390.89 | 2021-2024 | Intellis Adaptivestim |
| Nalu Medical, INC. | $382.61 | 2021-2024 | Nalu Neurostimulation System |
| Abbvie INC. | $345.71 | 2021-2025 | Ubrelvy, Qulipta, Botox |
| Lundbeck LLC | $330.49 | 2020-2025 | Vyepti |
| Depuy Synthes Sales INC. | $280.17 | 2019 | |
| Amgen INC. | $259.10 | 2019-2025 | Repatha |
| Qol Medical, LLC | $254.89 | 2020-2025 | Sucraid, Sucraid |
| Nevro Corp. | $234.93 | 2019-2022 | |
| Relievant Medsystems, INC. | $201.99 | 2021-2023 | Intracept |
Show all 59 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bahman Shamloo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.